- Home
- CET vs IRON Comparison
CET vs IRON Comparison
Compare CET & IRON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CET
- IRON
- Stock Information
- Founded
- CET 1929
- IRON 2017
- Country
- CET United States
- IRON United States
- Employees
- CET N/A
- IRON N/A
- Industry
- CET Finance/Investors Services
- IRON Biotechnology: Pharmaceutical Preparations
- Sector
- CET Finance
- IRON Health Care
- Exchange
- CET Nasdaq
- IRON Nasdaq
- Market Cap
- CET 1.2B
- IRON 1.4B
- IPO Year
- CET N/A
- IRON N/A
- Fundamental
- Price
- CET $46.61
- IRON $46.68
- Analyst Decision
- CET
- IRON Strong Buy
- Analyst Count
- CET 0
- IRON 9
- Target Price
- CET N/A
- IRON $93.89
- AVG Volume (30 Days)
- CET 22.7K
- IRON 354.8K
- Earning Date
- CET 01-01-0001
- IRON 05-07-2025
- Dividend Yield
- CET 4.84%
- IRON N/A
- EPS Growth
- CET 26.33
- IRON N/A
- EPS
- CET 9.95
- IRON N/A
- Revenue
- CET $23,698,535.00
- IRON N/A
- Revenue This Year
- CET N/A
- IRON N/A
- Revenue Next Year
- CET N/A
- IRON N/A
- P/E Ratio
- CET $4.67
- IRON N/A
- Revenue Growth
- CET 11.75
- IRON N/A
- 52 Week Low
- CET $40.24
- IRON $30.82
- 52 Week High
- CET $49.51
- IRON $68.73
- Technical
- Relative Strength Index (RSI)
- CET 60.83
- IRON 49.90
- Support Level
- CET $45.77
- IRON $44.85
- Resistance Level
- CET $46.91
- IRON $47.36
- Average True Range (ATR)
- CET 0.68
- IRON 2.23
- MACD
- CET -0.06
- IRON -0.12
- Stochastic Oscillator
- CET 49.43
- IRON 37.58
About CET Central Securities Corporation
Central Securities Corp is a non-diversified closed-end management investment company. Its investment objective is long-term growth of capital. The company invests in common stocks, bonds, convertible bonds, preferred stocks, convertible preferred stocks, warrants, options real estate, or short-term obligations of governments, banks, and corporations.
About IRON Disc Medicine Inc.
Disc Medicine Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for hematologic diseases. It aims to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for erythropoietic porphyrias (EPs) including erythropoietic protoporphyria (EPP), X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF) and anemia of chronic kidney disease (CKD); and DISC-3405 for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, the Company's preclinical programs include DISC-0998.